Genmab A/S ADS (GMAB) Price and Market Data

Genmab A/S ADS is a Copenhagen-based biotechnology company focused on developing antibody therapeutics for cancer treatment. Its proprietary antibody technology platforms include DuoBody, HexaBody, DuoHexaBody, and HexElect. In partnership with Johnson & Johnson, Genmab developed Darzalex, its flagship product and a widely recognized standard of care for multiple myeloma. The company’s marketed portfolio also includes Tepezza for thyroid eye disease, partnered with Horizon; Kesimpta for relapsing multiple sclerosis, partnered with Novartis; Rybrevant for non-small cell lung cancer, partnered with Johnson & Johnson; Tivdak for cervical cancer, partnered with Seagen; and Epkinly for diffuse large B-cell lymphoma, partnered with AbbVie. Genmab also maintains a pipeline of candidates targeting additional oncology indications.